Icosapent ethyl is derived from fish oil, but it is not the same thing as the fish oil supplements you find on store shelves. It is a highly purified, prescription-only form of a single omega-3 fatty acid called EPA (eicosapentaenoic acid), sold under the brand name Vascepa. Standard fish oil supplements contain a mix of two main omega-3s, EPA and DHA, along with other fats, and they are not held to the same purity or dosing standards.
That distinction matters more than it might seem. The two products behave differently in the body, have different effects on cholesterol, and only one has been proven in large clinical trials to reduce the risk of heart attacks and strokes.
How Icosapent Ethyl Differs From Fish Oil
The core difference is composition. Icosapent ethyl contains only EPA in a highly purified ethyl ester form. Over-the-counter fish oil capsules typically deliver a combination of EPA and DHA in varying ratios, often with other fatty acids mixed in. Because fish oil supplements are classified as dietary supplements rather than drugs, their actual omega-3 content can vary from what’s listed on the label, and they don’t undergo the same rigorous testing that prescription medications do.
This isn’t just a quality-control issue. EPA and DHA have meaningfully different effects on blood lipids. EPA has little impact on LDL (“bad”) cholesterol. DHA, on the other hand, can raise LDL cholesterol, particularly in people who already have very high triglycerides. That’s a problem, because those are exactly the patients most likely to reach for a fish oil product. By isolating EPA and removing DHA entirely, icosapent ethyl lowers triglycerides without the trade-off of pushing LDL cholesterol higher.
DHA does have some compensating effects: it increases LDL particle size, which may make those particles less harmful, and it raises HDL (“good”) cholesterol. But no large cardiovascular outcomes trial has demonstrated that a combined EPA-DHA supplement reduces heart attacks or strokes the way purified EPA has.
What It’s FDA-Approved to Treat
The FDA has approved icosapent ethyl for two uses. The first is lowering triglycerides in adults with severe levels (500 mg/dL or higher), where it is used alongside dietary changes. The second, broader indication is reducing the risk of heart attack, stroke, coronary procedures, and hospitalization for unstable angina in adults who have elevated triglycerides (150 mg/dL or higher) and either established cardiovascular disease or diabetes with two or more additional heart risk factors. In both cases, it is meant to be added on top of statin therapy, not used as a replacement.
No over-the-counter fish oil supplement carries either of these approved indications.
The Trial That Changed Its Status
The landmark study behind icosapent ethyl’s cardiovascular approval was REDUCE-IT, a trial of more than 8,000 patients already on statins who had elevated triglycerides. Patients took either 4 grams of icosapent ethyl daily (2 grams twice a day) or a placebo.
The results were striking. Major cardiovascular events, a composite of cardiovascular death, nonfatal heart attack, nonfatal stroke, coronary procedures, and hospitalization for unstable angina, occurred in 17.2% of the icosapent ethyl group compared to 22.0% in the placebo group. That translates to a 25% relative risk reduction. When the outcome was narrowed to just cardiovascular death, heart attack, and stroke, the reduction was 26%, with events dropping from 14.8% to 11.2%.
These benefits held even in patients whose LDL cholesterol was already very well controlled by statins. A secondary analysis found a 34% reduction in the primary composite endpoint among those patients, suggesting the drug’s benefits go beyond simple triglyceride lowering.
Known Side Effects
Icosapent ethyl is generally well tolerated, but two side effects stood out in clinical trials. Hospitalization for atrial fibrillation or flutter (an irregular heart rhythm) occurred in 3.1% of patients taking icosapent ethyl compared to 2.1% on placebo. Serious bleeding events occurred in 2.7% of the treatment group versus 2.1% on placebo, though that difference did not reach statistical significance.
These rates are relatively low in absolute terms, but they’re worth weighing, especially for people already at risk for irregular heart rhythms or those taking blood thinners. The 2026 joint guidelines from the American College of Cardiology and the American Heart Association specifically note that the benefits and risks of bleeding and atrial arrhythmias should be considered on an individual basis.
Where It Fits in Current Guidelines
Icosapent ethyl is currently the only triglyceride-lowering medication that has been shown to reduce cardiovascular events when added to statin therapy. That unique position has earned it a place in the latest ACC/AHA lipid management guidelines, which describe it as a reasonable option for adults aged 50 and older with persistently elevated triglycerides, or for people with diabetes and at least one additional cardiovascular risk factor.
The guidelines are careful to frame it as something to consider rather than a blanket recommendation for everyone with high triglycerides. It is positioned as an add-on for patients who are already on optimized statin therapy and still carry residual cardiovascular risk.
Why You Can’t Substitute Fish Oil
It’s tempting to think that taking enough fish oil capsules could replicate the effects of icosapent ethyl. The math doesn’t work out for several reasons. To match the 4-gram daily dose of pure EPA in icosapent ethyl, you would need to take a large number of standard fish oil capsules, each of which typically contains only a few hundred milligrams of EPA alongside a comparable amount of DHA. That means you’d also be consuming significant amounts of DHA, which as noted can raise LDL cholesterol.
Beyond the compositional problem, supplement-grade fish oil has never been tested in a trial like REDUCE-IT. Several large trials of standard omega-3 supplements have failed to show cardiovascular benefit. The purity, dose, and single-ingredient formulation of icosapent ethyl appear to be essential to its clinical effects, not incidental.
For general health, fish oil supplements remain popular and may have modest benefits for some people. But for patients with elevated triglycerides and cardiovascular risk who need a proven, measurable reduction in heart events, icosapent ethyl occupies a category that store-bought fish oil simply does not.